Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (218)	5/15/2007 6:09:25 PM
From: david nordic	Read Replies (1) \| Respond to of 507

ENZON is delivering new peg products starting with PFE's irinotecan. Shearwater is behind all the peg products for the past 10 years. NKTR / Enzon to avoid a legal fight cross liecenced each other patents.Nktr is pegging the Irninotecan molecule. Enzon has already failed doing it once. NKTR(Shearwater) recently recieved several approved patents. Too soon to see yet. There are more than a few companies pursuing this direction of pegging. The CEO founded Graffinity, and did a stint at Affymax: Hematide is AFFY and is also NKTR. Maybe NKTR's patents are already involved? Funny how Graffinity is working on peg with NKTR for NKTR by NKTR. NKTR newer patents are for much smaller peptides. Germany's Complex Biosystems. I will keep track of this company. NKTR has a 20 year leap on them.